Health Care/Hospital

WuXi ATU Opens New Manufacturing Facility to Further Enhance Its CTDMO Services for Global Customers

PHILADELPHIA, Oct. 17, 2021 /PRNewswire/ -- WuXi Advanced Therapies Inc. (WuXi ATU) – a wholly owned subsidiary of WuXi AppTec – today announced the opening of its new process development and commercial manufacturing facility in Lin-gang, Shanghai. WuXi ATU is a leading Contract, Testing, Develop...

2021-10-18 11:05 2638

Concord Medical Files 2020 Annual Report on Form 20-F

BEIJING, Oct. 15, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM ), a healthcare provider specialized in c...

2021-10-16 06:00 4644

Neusoft Ranks Top in China Healthcare Security Informatization Market

SHENYANG, China, Oct. 15, 2021 /PRNewswire/ -- According to the Market Shares of Healthcare Security Information System ofChina 2020: Building a New Healthcare Security Information System recently released by International Data Corporation (IDC) for the first time, Neusoft Corporation ("Neusoft",...

2021-10-15 23:06 3915

CellOrigin secured a new round of investment for developing its globally proprietary iPSC-CAR-Macrophage technology platform

HANGZHOU, China, Oct. 15, 2021 /PRNewswire/ -- On Oct. 11th, 2021, CellOrigin Inc. released data about its second generation of iPSC-CAR-Macrophage which has a genetically integrated secondary signal to confer controlled CAR-iMac polarization, in the 5th International Conference of IGC China, 202...

2021-10-15 20:50 2459

Akeso is Rapidly Advancing The Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma

HONG KONG, Oct. 15, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the Company's self-developed innovative drug candidate, IL-4R monoclonal antibody (AK120), was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration ofthe People...

2021-10-15 12:44 2582

GV20 Oncotherapy Completes Series B Financing to Advance Pipeline into the Clinic and Expand Immuno-Oncology Drug Discovery Platform

SHANGHAI, Oct. 14, 2021 /PRNewswire/ -- GV20 Oncotherapy, a biotechnology company with unique expertise in novel target identification and antibody drug discovery in immuno-oncology, today announced the completion of its Series B financing. This round of financing was led by Coatue Management,...

2021-10-14 23:55 2186

Posture360 Receives Venture Capital to Drive Growth in Healthcare Industry

NEW YORK, Oct. 14, 2021 /PRNewswire/ -- Posture360, an industry leader in smart wearable technologies, has received an investment from Legendary Ventures as it  is set to launch PostureSense®, the next-generation Smart Shirt that tracks, monitors, and analyzes physical activities (with real-time b...

2021-10-14 21:00 2228

Roan Holdings Group Announces Agreement to Set Up Joint Venture to Expand in Consumer Health Services Market

BEIJING and HANGZHOU, China, Oct. 14, 2021 /PRNewswire/ -- Roan Holdings Group Co., Ltd. ("Roan" or the "Company") (OTC Pink: RAHGF and RONWF), a provider of diversified solutions in financial, insurance and healthcare related products and management services, today announced that the Company's s...

2021-10-14 20:00 2999

BioAgilytix Closes Acquisition of Australia-based 360biolabs®

Following final government approval, 360biolabs, a BioAgilytix company, adds world-class virology & immunology expertise and LC/MS/MS small molecule capabilities to the company, enabling support of bioanalytical services across all geographies and development stages DURHAM, N.C., Oct. 14, 2021 ...

2021-10-14 19:00 2366

Qilian International Holding Group Limited Received Approval for Oxytetracycline API Export to Egypt

JIUQUAN, China, Oct. 13, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced that on September 14, 2021, through its subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd. (the "...

2021-10-13 20:00 2810

I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China

* Completed patient enrollment in phase 3 registrational trial of felzartamab in combination with lenalidomide for second-line treatment of multiple myeloma (MM) * Felzartamab for MM third-line treatment is on track for BLA submission in Q4 2021 * New IND application for combination of felz...

2021-10-13 20:00 2019

Shanghai, industry partners to co-build world-class biopharma industry cluster

SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- This is a report from China.org.cn: The 2021 International Biopharma Industry Week opened in Shanghai on Oct. 11, bringing together industry gurus, research minds, investors, and government representatives to discuss the latest trends in the biopharmaceutic...

2021-10-13 19:43 2059

The CDE Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients

SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced that the Center for Drug Evaluation (CDE) NMPA has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients with ...

2021-10-13 15:47 1805

AUM Biosciences announces closing of USD $27Million in a "Series A" Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies

SINGAPORE, Oct. 12, 2021 /PRNewswire/ -- AUM Biosciences (AUM) today announced the successful completion of USD$27 million series A funding round. This will fuel AUM's vision of developing a world class biotech pipeline focused on drugging what many consider as the undruggable targets, as well ...

2021-10-13 02:30 2306

Accelerate Innovation Towards the Future,SAB of Winhealth Pharma Formally Established

HANGZHOU, China, Oct. 12, 2021  /PRNewswire/ -- On October 12, 2021, Hong Kong Winhealth Pharma Group, (hereinafter referred to as "Winhealth Pharma") announced the formal establishment of its Scientific Advisory Board (SAB), aiming to further expand and optimize the Group's strategic layout in m...

2021-10-12 23:45 3425

ActionIQ Expands Its CDP Offering into the Healthcare Industry

Completes HIPAA Type I Certification, Is Recertified in SOC 2 Type II Standards NEW YORK, Oct. 12, 2021 /PRNewswire/ -- ActionIQ, the leading Enterprise Customer Data Platform (CDP), today announced that it has expanded its CDP into the healthcare vertical by completing their compliance audit for...

2021-10-12 22:00 2258

Integrated Media Technology Limited Enters US$11 Million Conditional Agreement to Acquire an Internet of Medical Things (IoMT) Company

SYDNEY, Oct. 12, 2021 /PRNewswire/ -- Integrated Media Technology Limited (NASDAQ: IMTE) ("IMTE" or the "Company"), announces today the signing of a conditional sale and purchase agreement to acquire 100% equity interest in Magnum International Holdings Limited ("Magnum"), forUS$11 million which ...

2021-10-12 20:30 3121

CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan

TOKYO, Oct. 12, 2021 /PRNewswire/ -- Jadeite Medicines Inc. ("Jadeite"), a biopharmaceutical company that is backed bySingapore's CBC Group ("CBC") and committed to addressing critical unmet medical needs for patients inJapan, today entered into an exclusive licensing agreement with Albireo Pharm...

2021-10-12 20:30 1801

Shanghai Pharmaceuticals and Luca Healthcare Announce a Strategic Collaboration to Provide Home Drug Delivery to Rare Disease Patients on Luca Healthcare's Patient Management Platform

SHANGHAI, Oct. 12, 2021 /PRNewswire/ -- SPH Health Commerce, the Direct-to-Patient ("DTP") retail pharmacy subsidiary of Shanghai Pharmaceuticals and Luca Healthcare,China's category leader in clinically validated, software-based screening, treatment and management tools, today announced a strat...

2021-10-12 19:21 3050

NeoPlex (TM) HPV29 Detection, a new molecular detection kit from Genematrix, acquires European CE-IVD certification

* Real-time PCR-based human papillomavirus (HPV) detection product is launched. * Simultaneous HPV detection and genotyping of 29 HPV types are available. PANGYO,South Korea, Oct. 12, 2021 /PRNewswire/ -- Genematrix (KRX 109820), specialized in real-time PCR based molecular diagnostics, annou...

2021-10-12 16:00 2172
1 ... 318319320321322